NCT05749445招募中不适用
Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients: a Multicenter Retrospective Study in China
First People's Hospital of Hangzhou1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2022年12月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- The prevalence of inappropriate use of nirmatrelvir-ritonavir
研究概览
简要总结
The primary objective of the study was to assess the appropriateness of antiviral therapy with nirmatrelvir-ritonavir in hospitalized patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •hospitalized patients receiving at least one dose nirmatrelvir-ritonavir
排除标准
- 未提供
研究组 & 干预措施
Nirmatrelvir-Ritonavir
Hospitalized patients receiving at least one dose Nirmatrelvir-Ritonavir
干预措施: Nirmatrelvir-Ritonavir (Drug)
结局指标
主要结局
The prevalence of inappropriate use of nirmatrelvir-ritonavir
时间窗: baseline
Four aspects were evaluated to identify the rationality of prescribing NMVr, including indication, administration (dose, timing, and duration), contraindications, and drug-drug interactions.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19Omicron Variant of COVID-19NCT05813600Xiangao Jiang58
已完成
2 期
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/RitonavirCOVID-19NCT05567952Pfizer436
已完成
不适用
Assessment of indication and efficacy of anti-viral therapy based on mucosal PCR assay in active UC patients with CMV infection.lcerative colitisJPRN-UMIN000022588Department of Gastroenterology and Hepatology, Kyoto University Hospital120
尚未招募
3 期
Study of antiviral nutraceutical PICOVRID in COVID 19 patientsCTRI/2020/07/026534Indian Institute of Technology Bombay
撤回
2 期
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Coronavirus Disease 2019 (COVID-19)ImmunocompromisedHospitalizationChild, HospitalizedNCT05545319Pfizer